The investment case for hepatitis B and C in South Africa: adaptation and innovation in policy analysis for disease program scale-up
Summary Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have […]